Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.

Voss RK, Feng L, Lee JE, Perrier ND, Graham PH, Hyde SM, Nieves-Munoz F, Cabanillas ME, Waguespack SG, Cote GJ, Gagel RF, Grubbs EG.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2807-2813. doi: 10.1210/jc.2017-00317.

PMID:
28609830
2.

Zebrafish GDNF and its co-receptor GFRα1 activate the human RET receptor and promote the survival of dopaminergic neurons in vitro.

Saarenpää T, Kogan K, Sidorova Y, Mahato AK, Tascón I, Kaljunen H, Yu L, Kallijärvi J, Jurvansuu J, Saarma M, Goldman A.

PLoS One. 2017 May 3;12(5):e0176166. doi: 10.1371/journal.pone.0176166. eCollection 2017.

3.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

PMID:
28447912
5.

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.

Ye S, Zhao XY, Hu XG, Li T, Xu QR, Yang HM, Huang DS, Yang L.

Oncol Rep. 2017 Apr;37(4):2215-2226. doi: 10.3892/or.2017.5494. Epub 2017 Mar 8.

6.

Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.

Mathiesen JS, Habra MA, Bassett JHD, Choudhury SM, Balasubramanian SP, Howlett TA, Robinson BG, Gimenez-Roqueplo AP, Castinetti F, Vestergaard P, Frank-Raue K.

J Clin Endocrinol Metab. 2017 Jun 1;102(6):2069-2074. doi: 10.1210/jc.2016-3640.

PMID:
28323957
7.

MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.

Spitschak A, Meier C, Kowtharapu B, Engelmann D, Pützer BM.

Mol Cancer. 2017 Jan 26;16(1):24. doi: 10.1186/s12943-016-0563-x.

8.

Different RET gene mutation-induced multiple endocrine neoplasia type 2A in 3 Chinese families.

Liu Q, Tong D, Yuan W, Liu G, Yuan G, Lan W, Zhang D, Zhang J, Huang Z, Zhang Y, Jiang J.

Medicine (Baltimore). 2017 Jan;96(3):e5967. doi: 10.1097/MD.0000000000005967.

9.

ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.

Bagheri-Yarmand R, Williams MD, Grubbs EG, Gagel RF.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):933-941. doi: 10.1210/jc.2016-2878.

PMID:
27935748
10.

A Novel Zebrafish ret Heterozygous Model of Hirschsprung Disease Identifies a Functional Role for mapk10 as a Modifier of Enteric Nervous System Phenotype Severity.

Heanue TA, Boesmans W, Bell DM, Kawakami K, Vanden Berghe P, Pachnis V.

PLoS Genet. 2016 Nov 30;12(11):e1006439. doi: 10.1371/journal.pgen.1006439. eCollection 2016 Nov.

11.

EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.

Chang H, Sung JH, Moon SU, Kim HS, Kim JW, Lee JS.

Yonsei Med J. 2017 Jan;58(1):9-18. doi: 10.3349/ymj.2017.58.1.9.

12.

A cohort study on 10-year survival of sporadic medullary thyroid carcinoma with somatic RET mutation.

Chuang LL, Hwang DY, Tsai KB, Chan HM, Chiang FY, Hsiao PJ.

Kaohsiung J Med Sci. 2016 Nov;32(11):545-551. doi: 10.1016/j.kjms.2016.08.012. Epub 2016 Oct 14.

13.

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.

Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, Plodkowski A, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, Kris MG.

Lancet Oncol. 2016 Dec;17(12):1653-1660. doi: 10.1016/S1470-2045(16)30562-9. Epub 2016 Nov 4.

PMID:
27825636
14.

Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors.

Han M, Li S, Ai J, Sheng R, Hu Y, Hu Y, Geng M.

Bioorg Med Chem Lett. 2016 Dec 1;26(23):5679-5684. doi: 10.1016/j.bmcl.2016.10.061. Epub 2016 Oct 24.

PMID:
27815117
15.

Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.

Yoon H, Shin I, Nam Y, Kim ND, Lee KB, Sim T.

Eur J Med Chem. 2017 Jan 5;125:1145-1155. doi: 10.1016/j.ejmech.2016.10.050. Epub 2016 Oct 22.

PMID:
27814560
16.

RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease.

Su X, He C, Ma J, Tang T, Zhang X, Ye Z, Long Y, Shao Q, Shao J, Yang A.

PLoS One. 2016 Nov 1;11(11):e0165596. doi: 10.1371/journal.pone.0165596. eCollection 2016.

17.

Modeling human MLL-AF9 translocated acute myeloid leukemia from single donors reveals RET as a potential therapeutic target.

Barabé F, Gil L, Celton M, Bergeron A, Lamontagne V, Roques É, Lagacé K, Forest A, Johnson R, Pécheux L, Simard J, Pelloux J, Bellemare-Pelletier A, Gagnon E, Hébert J, Cellot S, Wilhelm BT.

Leukemia. 2017 May;31(5):1166-1176. doi: 10.1038/leu.2016.302. Epub 2016 Oct 26.

PMID:
27780967
18.

Association Between RET (rs1800860) and GFRA1 (rs45568534, rs8192663, rs181595401, rs7090693, and rs2694770) Variants and Kidney Size in Healthy Newborns.

Kaczmarczyk M, Loniewska B, Kuprjanowicz A, Binczak-Kuleta A, Goracy I, Ryder M, Taryma-Lesniak O, Ciechanowicz A.

Genet Test Mol Biomarkers. 2016 Oct;20(10):624-628. Epub 2016 Aug 17.

PMID:
27533506
19.

The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.

Grey W, Hulse R, Yakovleva A, Genkova D, Whitelaw B, Solomon E, Diaz-Cano SJ, Izatt L.

Endocr Pathol. 2017 Mar;28(1):41-48. doi: 10.1007/s12022-016-9451-6.

PMID:
27704398
20.

<i>RET</i> Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.

Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R.

Clin Cancer Res. 2017 Apr 15;23(8):1988-1997. doi: 10.1158/1078-0432.CCR-16-1679. Epub 2016 Sep 28.

PMID:
27683183

Supplemental Content

Loading ...
Support Center